QuitGuide for American Indians: Aims 2 & 3

Sponsor
Masonic Cancer Center, University of Minnesota (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05447156
Collaborator
(none)
134
1
3
22.9
5.8

Study Details

Study Description

Brief Summary

Aim 2: To assess the preliminary feasibility and acceptability of a tailored smoking cessation app prototype (here forward called tailored QuitGuide) among American Indian (AI) smokers.

Aim 3: To test feasibility, acceptability, and preliminary efficacy of the tailored QuitGuide for smoking cessation among AIs.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Tailored QuitGuide app
  • Behavioral: Standard QuitGuide app
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
134 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Aim 2: All participants in this aim will use the tailored QuitGuide app Aim 3: Participants will be randomized to either the tailored QuitGuide app or the standard version of the QuitGuide app for 5 weeks.Aim 2: All participants in this aim will use the tailored QuitGuide app Aim 3: Participants will be randomized to either the tailored QuitGuide app or the standard version of the QuitGuide app for 5 weeks.
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
QuitGuide for American Indians: Aims 2 & 3
Anticipated Study Start Date :
Sep 1, 2022
Anticipated Primary Completion Date :
Jul 30, 2023
Anticipated Study Completion Date :
Jul 30, 2024

Arms and Interventions

Arm Intervention/Treatment
Other: Aim 2: Tailored App (pilot run of Aim 3)

All participants will use the tailored QuitGuide app, a smoking cessation app, downloaded to their personal phone.

Behavioral: Tailored QuitGuide app
This is an app not available to the public. It was developed/tailored based on an app available to the public and can be downloaded.

Experimental: Aim 3:Tailored App

Randomized subset of participants will use the tailored QuitGuide app, a smoking cessation app, downloaded to their personal phone.

Behavioral: Tailored QuitGuide app
This is an app not available to the public. It was developed/tailored based on an app available to the public and can be downloaded.

Placebo Comparator: Aim 3: Standard App

Randomized subset of participants will use the standard QuitGuide app, a smoking cessation app available to the public, downloaded to their personal phone.

Behavioral: Standard QuitGuide app
This is an app is available to the public.

Outcome Measures

Primary Outcome Measures

  1. Frequency of app use [2 weeks post enrollment for aim 2 and 5 weeks post enrollment for aim 3]

    The number of times the app is initiated per day will be measured using data from Smokefree.gov. If a participant does not use the app on a particular day, Smokefree.gov records this as non-use or 0 for that day. The total number of times will be summarized for analysis by totaling the number of times the app is initiated from randomization to 5 weeks post-randomization.

Secondary Outcome Measures

  1. Frequency of app use [1 week post-randomization for aim 3/ Not applicable for aim 2]

    The number of times the app is initiated per day will be measured using data from Smokefree.gov. If a participant does not use the app on a particular day, Smokefree.gov records this as non-use or 0 for that day. The total number of times will be summarized for analysis by totaling the number of times the app is initiated from randomization to 5 weeks post-randomization.

  2. Frequency of interactions with various app features (e.g. quit tips, trigger list) over the 5 weeks [2 weeks post enrollment for aim 2 and 5 weeks post enrollment for aim 3]

    The number of times the app is initiated per day will be measured using data from Smokefree.gov. If a participant does not use the app on a particular day, Smokefree.gov records this as non-use or 0 for that day. The total number of times will be summarized for analysis by totaling the number of times the app is initiated from randomization to 5 weeks post-randomization.

  3. Study attrition measured as percentage of randomized participants that complete the final phone interview at 5 weeks [5 weeks post enrollment aim 3]

    Percentage of randomized participants that complete the final phone interview at 5 weeks

  4. Frequency of returning saliva sample by 2 weeks post the week 5 interview [5 weeks post enrollment aim 3]

    Count of randomized participants that return saliva sample 2 weeks after the 5 weeks post enrollment (end of intervention)

  5. Usability of App Design measured using System Usability scale (SUS) [5 weeks post enrollment]

    How will this scale be used? how are results reported? Would there be an average/percentage?

  6. Acceptability of overall app (i.e., how likely would you be to recommend the app) and various app components (e.g. quit tips, trigger list) measured as Likert-scale responses [5 weeks post enrollment]

    Acceptability of overall app- will you use a scoring: how is this going to be summarized? various app components (e.g. quit tips, trigger list) measured as Likert-scale - this too broad for ct.gov they will likely reject this comment. We can discard or specifically break into components.

  7. Fit of app with culture measured as Likert-scale responses [5 weeks post enrollment]

    How will this scale be used? how are results reported? Would there be an average/percentage?

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • American Indian person based on self-report

  • Age ≥ 18 years

  • Interested in quitting smoking

  • Smoke ≥ 3 commercial tobacco cigarette per day (CPD) in the past 30 days

o Use of other commercial tobacco products (e.g., e-cigarettes) is permitted if they report cigarettes being their primary product

  • Smartphone ownership with the ability to download applications and sufficient data to complete research procedures
Exclusion Criteria:
  • Aim 2

• Does not speak or read English

  • Aim 3

  • Participation in Aim 2

  • New or change in pharmacotherapy for smoking cessation (includes: nicotine gum, patch, lozenge, inhaler OR medications Chantix/Wellbtrutin/Zyban/Bupropion) in past month

  • Does not speak or read English

Contacts and Locations

Locations

Site City State Country Postal Code
1 Masonic Cancer Center - University of Minnesota Minneapolis Minnesota United States 55455

Sponsors and Collaborators

  • Masonic Cancer Center, University of Minnesota

Investigators

  • Principal Investigator: Dana Caroll, PhD, Masonic Cancer Center, Univeristy of Minnesota

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Masonic Cancer Center, University of Minnesota
ClinicalTrials.gov Identifier:
NCT05447156
Other Study ID Numbers:
  • SPH-2022-30604
  • MCC CPRC
First Posted:
Jul 7, 2022
Last Update Posted:
Aug 5, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 5, 2022